Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methoxsalen + ECP
- Development stage
- Unknown
- Lead developer
- Mallinckrodt
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
Methoxsalen + ECP refers to the use of the small molecule drug methoxsalen in combination with extracorporeal photopheresis (ECP), a cell therapy procedure. Methoxsalen is a furocoumarin that, upon activation by ultraviolet A (UVA) light, intercalates into DNA and forms cross-links, thereby inhibiting DNA synthesis and function. In clinical practice, this combination is primarily used for immunomodulation in conditions such as steroid-refractory or steroid-intolerant chronic graft versus host disease (cGvHD) following allogeneic hematopoietic stem cell transplantation. The process involves collecting blood from the patient, treating it ex vivo with methoxsalen and UVA light using specialized systems like THERAKOS CELLEX, and then reinfusing it back into the patient[1][3][5][8]. Methoxsalen acts as a photosensitizer while ECP provides an immunomodulatory effect through treated leukocytes.
- Brand names
- Oxsoralen
- Other names
- 8-methoxypsoralenXanthotoxinammoidin
02
Targets
DNA
Beyond the preview
Go deeper on Methoxsalen + ECP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Methoxsalen + ECP.